Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes - Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model

Monica Rodolfo, Carolina Salvi, Cinzia Bassi, Giorgio Parmiani

Research output: Contribution to journalArticle

Abstract

We have used a BALB/c colonic adenocarcinoma (C-26) to evaluate the therapeutic potential of recombinant interleukin-2 (rIL-2) at high and low dosages in combination with or without lymphokine-activated killers (LAK) or tumor-specific, immune lymphocytes in either an adjuvant spontaneous or an artificial metastasis system. Most (≈80%) of the mice that underwent s.c. C-26 tumor excision were shown to die of spontaneous metastasis with lung involvement by 1-4 months after excision. Postsurgical systemic treatment with low-dose rIL-2 (3 × 104 U/day, i.p.) increased the survival rate to 31% as compared to 21% (not significant) in excised controls while administration of high-dose rIL-2 (8 × 104 U/day) led to 53% survival (P

Original languageEnglish
Pages (from-to)28-36
Number of pages9
JournalCancer Immunology, Immunotherapy
Volume31
Issue number1
DOIs
Publication statusPublished - Jan 1990

Fingerprint

Adoptive Immunotherapy
Lymphokine-Activated Killer Cells
Interleukin-2
Colon
Theoretical Models
Lymphocytes
Neoplasm Metastasis
Carcinoma
Neoplasms
Lymphokines
Interleukin-3
Interleukin-8
Adenocarcinoma
Therapeutics
Lung

ASJC Scopus subject areas

  • Oncology
  • Immunology
  • Cancer Research

Cite this

@article{e39a182d78ac4afb94063dbf6832766e,
title = "Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes - Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model",
abstract = "We have used a BALB/c colonic adenocarcinoma (C-26) to evaluate the therapeutic potential of recombinant interleukin-2 (rIL-2) at high and low dosages in combination with or without lymphokine-activated killers (LAK) or tumor-specific, immune lymphocytes in either an adjuvant spontaneous or an artificial metastasis system. Most (≈80{\%}) of the mice that underwent s.c. C-26 tumor excision were shown to die of spontaneous metastasis with lung involvement by 1-4 months after excision. Postsurgical systemic treatment with low-dose rIL-2 (3 × 104 U/day, i.p.) increased the survival rate to 31{\%} as compared to 21{\%} (not significant) in excised controls while administration of high-dose rIL-2 (8 × 104 U/day) led to 53{\%} survival (P",
author = "Monica Rodolfo and Carolina Salvi and Cinzia Bassi and Giorgio Parmiani",
year = "1990",
month = "1",
doi = "10.1007/BF01742492",
language = "English",
volume = "31",
pages = "28--36",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes - Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model

AU - Rodolfo, Monica

AU - Salvi, Carolina

AU - Bassi, Cinzia

AU - Parmiani, Giorgio

PY - 1990/1

Y1 - 1990/1

N2 - We have used a BALB/c colonic adenocarcinoma (C-26) to evaluate the therapeutic potential of recombinant interleukin-2 (rIL-2) at high and low dosages in combination with or without lymphokine-activated killers (LAK) or tumor-specific, immune lymphocytes in either an adjuvant spontaneous or an artificial metastasis system. Most (≈80%) of the mice that underwent s.c. C-26 tumor excision were shown to die of spontaneous metastasis with lung involvement by 1-4 months after excision. Postsurgical systemic treatment with low-dose rIL-2 (3 × 104 U/day, i.p.) increased the survival rate to 31% as compared to 21% (not significant) in excised controls while administration of high-dose rIL-2 (8 × 104 U/day) led to 53% survival (P

AB - We have used a BALB/c colonic adenocarcinoma (C-26) to evaluate the therapeutic potential of recombinant interleukin-2 (rIL-2) at high and low dosages in combination with or without lymphokine-activated killers (LAK) or tumor-specific, immune lymphocytes in either an adjuvant spontaneous or an artificial metastasis system. Most (≈80%) of the mice that underwent s.c. C-26 tumor excision were shown to die of spontaneous metastasis with lung involvement by 1-4 months after excision. Postsurgical systemic treatment with low-dose rIL-2 (3 × 104 U/day, i.p.) increased the survival rate to 31% as compared to 21% (not significant) in excised controls while administration of high-dose rIL-2 (8 × 104 U/day) led to 53% survival (P

UR - http://www.scopus.com/inward/record.url?scp=0025098150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025098150&partnerID=8YFLogxK

U2 - 10.1007/BF01742492

DO - 10.1007/BF01742492

M3 - Article

C2 - 2306753

AN - SCOPUS:0025098150

VL - 31

SP - 28

EP - 36

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 1

ER -